In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: BioMed X and Ono Pharmaceutical Enter Joint Cancer Research Project
BioMed X and Ono Pharmaceutical Enter Joint Cancer Research Project
PharmaTimes
In 2020, there were over ten million deaths worldwide associated with cancer. The BioMed X Institute and Ono Pharmaceutical have announced a new joint research collaboration for cancer research.
Visit: BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research
BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research
BioSpace
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
Visit: BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research
BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research
Yahoo! Finance
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
Visit: DenovAI Biotech Creates Designer Antibodies for Any Disease
DenovAI Biotech Creates Designer Antibodies for Any Disease
AzoRobotics
A start-up named DenovAI, founded by a former EMBL staff scientist, is pioneering a revolutionary approach to expedite and reduce costs in antibody discovery.
Visit: Using artificial intelligence to discover therapeutic antibodies
Using artificial intelligence to discover therapeutic antibodies
EurekAlert!
Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics.
Visit: Using artificial intelligence to discover therapeutic antibodies
Using artificial intelligence to discover therapeutic antibodies
European Molecular Biology Laboratory (EMBL)
Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics.